Lupus patients in England in remission after pioneering NHS trial of GM therapy

A revolutionary therapy that genetically modifies a patient's own cells has put five lupus patients in England into remission, marking a significant medical breakthrough that doctors believe could offer a cure for the chronic autoimmune disease. The treatment, known as CAR T-cell therapy, involves extracting T lymphocytes, a type of white blood cell crucial for identifying and eliminating infected or damaged cells, and engineering them to specifically target and destroy the cells responsible for lupus. These modified T-cells are then infused back into the patient to effectively reset their immune system. While CAR T-cell therapy has already transformed cancer treatment, its successful application in lupus patients represents a new frontier. Medics at University College London hospitals foundation trust (UCLH) and University College London (UCL) successfully used the technique on nine patients with severe lupus who had not responded to previous treatments. Most of these patients suffered from lupus nephritis, a severe kidney complication.

“

These findings are truly groundbreaking and offer fresh hope to people living with lupus.

Of the nine patients recruited for the NHS trial, six received a lower dose of the CAR-T therapy and three received a higher dose. Within months, five of the patients on the lower dose, who have been monitored for an average of 11 months, achieved remission. Doctors are optimistic that the three patients on the higher dose, who have been followed for three months, will also achieve remission. Blood tests revealed rapid improvements in disease markers, including stabilized or improved kidney function, which had been compromised by the lupus. Lupus is a chronic autoimmune condition where the immune system mistakenly attacks healthy tissues, leading to widespread inflammation and damage to organs such as the kidneys, lungs, and heart. Symptoms can range from joint pain and skin issues to fatigue and severe organ inflammation. Globally, an estimated 5 million people have lupus, predominantly women.

“

While more research is needed, the possibility that CAR T-cell therapy could deliver an immune reset and potentially free patients from the cycle of chronic autoimmune disease marks a remarkable step forward.

Professor Karl Peggs, director of UCLH’s biomedical research centre, described the findings as "truly groundbreaking" and a source of "fresh hope" for lupus patients. He emphasized that while larger studies are necessary, CAR T-cell therapy presents the possibility of an immune system reset, potentially freeing patients from the continuous cycle of autoimmune disease. "If these results are confirmed in larger studies, the prospect of a cure for lupus may no longer be out of reach," Peggs stated. One of the patients, Katie Tinkler, reported being free of the main symptoms of the disease more than three decades after her diagnosis. She has since been able to ski for the first time in ten years and dance at her daughter's wedding, activities previously impossible due to the debilitating effects of lupus.

“

If these results are confirmed in larger studies, the prospect of a cure for lupus may no longer be out of reach.